Registration Dossier

Administrative data

Key value for chemical safety assessment

Additional information

Valeryl chloride was tested in the Ames reverse mutation assay (GLP compliant OECD guideline 471/472 study) using Salmonella typhimurium strains TA98, TA100, TA1535 and TA1537 and Escherichia coli WP2 uvr A at 20 to 5000 µg/plate (standard plate test) and 20 to 1500 µg/plate (preincubation test) with and without metabolic activation (BASF AG, 1997). No precipitation of the test substance was found. A bacteriotoxic effect was observed at doses from 1,500 µg/plate (standard plate test) or from 500 µg/plate (preincubation test). Under the conditions tested, an increase in the number of his+ or trp+ revertants was not observed both in the standard plate test and in the preincubation test either without S-9 mix or after the addition of a metabolising system.

Short description of key information:
Valeryl chloride did not cause gene mutations in Salmonella typhimurium and Escherichia coli (Ames test).

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the results of the Ames test, valeryl chloride does not need to be classified according to Directive 67/548/EEC and according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.